| Gene Symbol | ent-gene-e21647f6 |
| 2017 | Company founded in Bethesda, MD |
| 2018 | Series A financing: $5.5 million |
| 2020 | Series B financing: $12 million; SEE-Tx platform validated |
| 2021 | IPO on NASDAQ: $25 million gross proceeds |
| 2023 | GT-02287 enters Phase 1 clinical trials |
| 2024 | Phase 1b trial initiated in GBA1-PD |
| 2025 | Phase 1b interim data expected |
| KG Connections | 2 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |